{"protocolSection": {"identificationModule": {"nctId": "NCT00419952", "orgStudyIdInfo": {"id": "D5896C00022"}, "organization": {"fullName": "AstraZeneca", "class": "INDUSTRY"}, "briefTitle": "A Comparison of SYMBICORT\u00ae pMDI With Budesonide HFA pMDI in African American Subjects With Asthma.", "officialTitle": "A 52-week, Randomised, Double-blind, Parallel-group, Multi-centre, Phase IIIB Study Comparing the Long Term Safety of SYMBICORT\u00ae pMDI 160/4.5 mg x 2 Actuations Twice Daily to Budesonide HFA pMDI 160 mg x 2 Actuations Twice Daily in Adult/Adolescent (\u226512 Years) African American Subjects With Asthma"}, "statusModule": {"statusVerifiedDate": "2012-09", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2007-02"}, "primaryCompletionDateStruct": {"date": "2009-11", "type": "ACTUAL"}, "completionDateStruct": {"date": "2009-11", "type": "ACTUAL"}, "studyFirstSubmitDate": "2007-01-05", "studyFirstSubmitQcDate": "2007-01-05", "studyFirstPostDateStruct": {"date": "2007-01-09", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2010-11-30", "resultsFirstSubmitQcDate": "2012-09-28", "resultsFirstPostDateStruct": {"date": "2012-10-30", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2012-09-28", "lastUpdatePostDateStruct": {"date": "2012-10-30", "type": "ESTIMATED"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "AstraZeneca", "class": "INDUSTRY"}}, "descriptionModule": {"briefSummary": "The purpose of this study is to determine the effectiveness and safety of SYMBICORT\u00ae pMDI (a medication approved by the Food and Drug Administration, FDA) in the African American population."}, "conditionsModule": {"conditions": ["Asthma"], "keywords": ["Moderate Asthma", "Severe Asthma"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "QUADRUPLE", "whoMasked": ["PARTICIPANT", "CARE_PROVIDER", "INVESTIGATOR", "OUTCOMES_ASSESSOR"]}}, "enrollmentInfo": {"count": 742, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Symbicort", "type": "EXPERIMENTAL", "description": "Symbicort pMDI 160/4.5 ug x 2 actuations twice daily (BID)", "interventionNames": ["Drug: Budesonide/formoterol (SYMBICORT) pMDI"]}, {"label": "Budesonide", "type": "EXPERIMENTAL", "description": "Budesonide HFA pMDI 160 ug x 2 actuations BID", "interventionNames": ["Drug: Budesonide HFA pMDI"]}], "interventions": [{"type": "DRUG", "name": "Budesonide/formoterol (SYMBICORT) pMDI", "description": "Symbicort pMDI 160/4.5 ug x 2 actuations twice daily (BID)", "armGroupLabels": ["Symbicort"]}, {"type": "DRUG", "name": "Budesonide HFA pMDI", "description": "Budesonide HFA pMDI 160 ug x 2 actuations BID", "armGroupLabels": ["Budesonide"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Total Number of Asthma Exacerbations", "description": "An exacerbation was defined as symptomatic worsening requiring oral/systemic glucocorticoid therapy and/or emergency room visit and/or urgent care center visit and/or hospitalization.", "timeFrame": "52 Weeks"}], "secondaryOutcomes": [{"measure": "Asthma Exacerbations", "description": "Number of participants with at least 1 exacerbation", "timeFrame": "52 Weeks"}, {"measure": "QT Interval Corrected Using the Fridericia Formula Measured Via Electrocardiogram (ECG)", "description": "QT interval corrected using the Fridericia formula \\[QTc (Frid)\\] - Change from baseline to end of treatment", "timeFrame": "Baseline and 52 weeks"}, {"measure": "Number of Patients With Shift From Normal to High Rate of Total Ectopic Ventricular Beats as Measured by 24-hour Holter Monitor Assessment", "description": "Total ectopic ventricular (VE) beats - number of participants with shift from normal (\\<50) to high (\u226550) from baseline to visit 4.", "timeFrame": "Baseline and 2 weeks (visit 4)"}, {"measure": "Number of Patients With Shift From Normal to High Rate of Total Ectopic Supraventricular Beats as Measured by 24-hour Holter Monitor Assessment", "description": "Total ectopic supraventricular (VE) beats - number of participants with shift normal (\\<50) to high (\u226550) from baseline to visit 4.", "timeFrame": "Baseline and 2 weeks (visit 4)"}, {"measure": "Total Number of Ventricular Runs as Measured by 24-hour Holter Monitor Assessment", "description": "Total ventricular runs - number of participants with shift normal (\\<1) to high (\u22651) from baseline to week 2.", "timeFrame": "Baseline and 2 weeks (visit 4)"}, {"measure": "Diary Assessments - Rescue-free Day", "description": "Calculated as the number of rescue-free days divided by the number of non missing days in the baseline period times 100%. The results are expressed as the change in % rescue-free days in the baseline period and the active treatment period. A rescue-free day was one in which the patient answered \"no\" to having used rescue medication that day", "timeFrame": "baseline and 52 weeks"}, {"measure": "Diary Assessments - Symptom-free Day", "description": "Calculated as the number of symptom-free days divided by the number of non missing days in the baseline period times 100%. The results are expressed as the change in % symptom-free days in the baseline period and the active treatment period. A symptom-free day was one in which the patient answered \"no\" to having symptoms that day", "timeFrame": "baseline and 52 weeks"}, {"measure": "Diary Assessments - Asthma-control Day", "description": "Calculated as the number of asthma control days divided by the number of non missing days in the baseline period times 100%. The results are expressed as the change in % asthma control days in the baseline period and the active treatment period. An asthma control day was one in which the patient answered \"no\" to having symptoms and \"0\" to the use of rescue medication that day", "timeFrame": "baseline and 52 weeks"}, {"measure": "Onset of Effect Questionnaire (OEQ)", "description": "Number of participants with positive response to Item 2 in questionnaire \"During the past week,you could feel your study medication begin to work right away. A positive response was defined as a response of \"strongly agree\" or \"somewhat agree\"", "timeFrame": "1 week"}, {"measure": "Onset of Effect Questionnaire (OEQ)", "description": "Number of participants with positive response to Item 5 in questionnaire \"During the past week, you were satisfied with how quickly you felt your study medication begin to work.\" The scale was scored on a 5-point Likert scale from strongly agree to strongly disagree. A positive response was defined as a response of \"strongly agree\" or \"somewhat agree\"", "timeFrame": "1 week"}, {"measure": "Peak Expiratory Flow (PEF) in Morning", "description": "Change in AM PEF from baseline (mean over the 2 weeks run-in) to the average of the randomized treatment period.", "timeFrame": "baseline and 52 weeks"}, {"measure": "Forced Expiratory Volume in One Second (FEV1)", "description": "Change in pre-dose FEV1 from baseline (end of run-in, visit 3) to the average of the randomized treatment period", "timeFrame": "baseline and 52 weeks"}, {"measure": "Asthma Treatment Satisfaction Measure (ATSM)", "description": "Overall score - change from baseline to end of treatment. For 11 individual attributes, expectations were subtracted from the outcomes. This difference and the importance rating were combined in a weighted average which was then multiplied by the raw satisfaction measure. The final derived satisfaction measure was transformed to a 0 to 100 scale, with higher scores representing greater satisfaction.", "timeFrame": "Baseline and 52 weeks"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Male or Female, African American (self-reported), \u226512 years of age\n* Moderate to severe asthma requiring treatment with an inhaled corticosteroid\n* Diagnosis of asthma for at least 6 months\n\nExclusion Criteria:\n\n* Subjects requiring treatment with systemic corticosteroids (e.g., oral, parenteral, ocular)\n* Any significant disease or disorder that may jeopardize a subject's safety", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "12 Years", "stdAges": ["CHILD", "ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Christer Hultquist, MD", "affiliation": "AstraZeneca", "role": "STUDY_DIRECTOR"}], "locations": [{"facility": "Research Site", "city": "Birmingham", "state": "Alabama", "country": "United States", "geoPoint": {"lat": 33.52066, "lon": -86.80249}}, {"facility": "Research Site", "city": "Mobile", "state": "Alabama", "country": "United States", "geoPoint": {"lat": 30.69436, "lon": -88.04305}}, {"facility": "Research Site", "city": "Montgomery", "state": "Alabama", "country": "United States", "geoPoint": {"lat": 32.36681, "lon": -86.29997}}, {"facility": "Research Site", "city": "Muscle Shoals", "state": "Alabama", "country": "United States", "geoPoint": {"lat": 34.74481, "lon": -87.66753}}, {"facility": "Research Site", "city": "Phoenix", "state": "Arizona", "country": "United States", "geoPoint": {"lat": 33.44838, "lon": -112.07404}}, {"facility": "Research Site", "city": "Little Rock", "state": "Arkansas", "country": "United States", "geoPoint": {"lat": 34.74648, "lon": -92.28959}}, {"facility": "Research Site", "city": "Buena Park", "state": "California", "country": "United States", "geoPoint": {"lat": 33.86751, "lon": -117.99812}}, {"facility": "Research Site", "city": "Foothill Ranch", "state": "California", "country": "United States", "geoPoint": {"lat": 33.68652, "lon": -117.66077}}, {"facility": "Research Site", "city": "Long Beach", "state": "California", "country": "United States", "geoPoint": {"lat": 33.76696, "lon": -118.18923}}, {"facility": "Research Site", "city": "Los Angeles", "state": "California", "country": "United States", "geoPoint": {"lat": 34.05223, "lon": -118.24368}}, {"facility": "Research Site", "city": "Riverside", "state": "California", "country": "United States", "geoPoint": {"lat": 33.95335, "lon": -117.39616}}, {"facility": "Research Site", "city": "Rolling Hills Estates", "state": "California", "country": "United States", "geoPoint": {"lat": 33.78779, "lon": -118.35813}}, {"facility": "Research Site", "city": "San Diego", "state": "California", "country": "United States", "geoPoint": {"lat": 32.71533, "lon": -117.15726}}, {"facility": "Research Site", "city": "Stockton", "state": "California", "country": "United States", "geoPoint": {"lat": 37.9577, "lon": -121.29078}}, {"facility": "Research Site", "city": "Torrance", "state": "California", "country": "United States", "geoPoint": {"lat": 33.83585, "lon": -118.34063}}, {"facility": "Research Site", "city": "Winnetka", "state": "California", "country": "United States", "geoPoint": {"lat": 34.21334, "lon": -118.57203}}, {"facility": "Research Site", "city": "Colorado Springs", "state": "Colorado", "country": "United States", "geoPoint": {"lat": 38.83388, "lon": -104.82136}}, {"facility": "Research Site", "city": "Denver", "state": "Colorado", "country": "United States", "geoPoint": {"lat": 39.73915, "lon": -104.9847}}, {"facility": "Research Site", "city": "Newark", "state": "Delaware", "country": "United States", "geoPoint": {"lat": 39.68372, "lon": -75.74966}}, {"facility": "Research Site", "city": "Washington", "state": "District of Columbia", "country": "United States", "geoPoint": {"lat": 38.89511, "lon": -77.03637}}, {"facility": "Research Site", "city": "Altamonte Springs", "state": "Florida", "country": "United States", "geoPoint": {"lat": 28.66111, "lon": -81.36562}}, {"facility": "Research Site", "city": "Clearwater", "state": "Florida", "country": "United States", "geoPoint": {"lat": 27.96585, "lon": -82.8001}}, {"facility": "Research Site", "city": "Destin", "state": "Florida", "country": "United States", "geoPoint": {"lat": 30.39353, "lon": -86.49578}}, {"facility": "Research Site", "city": "Gainesville", "state": "Florida", "country": "United States", "geoPoint": {"lat": 29.65163, "lon": -82.32483}}, {"facility": "Research Site", "city": "Hollywood", "state": "Florida", "country": "United States", "geoPoint": {"lat": 26.0112, "lon": -80.14949}}, {"facility": "Research Site", "city": "Miami", "state": "Florida", "country": "United States", "geoPoint": {"lat": 25.77427, "lon": -80.19366}}, {"facility": "Research Site", "city": "Opa Locka", "state": "Florida", "country": "United States", "geoPoint": {"lat": 25.90232, "lon": -80.25033}}, {"facility": "Research Site", "city": "Orlando", "state": "Florida", "country": "United States", "geoPoint": {"lat": 28.53834, "lon": -81.37924}}, {"facility": "Research Site", "city": "Pensacola", "state": "Florida", "country": "United States", "geoPoint": {"lat": 30.42131, "lon": -87.21691}}, {"facility": "Research Site", "city": "Port Charlotte", "state": "Florida", "country": "United States", "geoPoint": {"lat": 26.97617, "lon": -82.09064}}, {"facility": "Research Site", "city": "South Miami", "state": "Florida", "country": "United States", "geoPoint": {"lat": 25.7076, "lon": -80.29338}}, {"facility": "Research Site", "city": "Tampa", "state": "Florida", "country": "United States", "geoPoint": {"lat": 27.94752, "lon": -82.45843}}, {"facility": "Research Site", "city": "West Palm Beach", "state": "Florida", "country": "United States", "geoPoint": {"lat": 26.71534, "lon": -80.05337}}, {"facility": "Research Site", "city": "Albany", "state": "Georgia", "country": "United States", "geoPoint": {"lat": 31.57851, "lon": -84.15574}}, {"facility": "Research Site", "city": "Atlanta", "state": "Georgia", "country": "United States", "geoPoint": {"lat": 33.749, "lon": -84.38798}}, {"facility": "Research Site", "city": "Augusta", "state": "Georgia", "country": "United States", "geoPoint": {"lat": 33.47097, "lon": -81.97484}}, {"facility": "Research Site", "city": "Columbus", "state": "Georgia", "country": "United States", "geoPoint": {"lat": 32.46098, "lon": -84.98771}}, {"facility": "Research Site", "city": "Gainesville", "state": "Georgia", "country": "United States", "geoPoint": {"lat": 34.29788, "lon": -83.82407}}, {"facility": "Research Site", "city": "Savannah", "state": "Georgia", "country": "United States", "geoPoint": {"lat": 32.08354, "lon": -81.09983}}, {"facility": "Research Site", "city": "Stone Mountain", "state": "Georgia", "country": "United States", "geoPoint": {"lat": 33.80816, "lon": -84.1702}}, {"facility": "Research Site", "city": "Chicago", "state": "Illinois", "country": "United States", "geoPoint": {"lat": 41.85003, "lon": -87.65005}}, {"facility": "Research Site", "city": "Peoria", "state": "Illinois", "country": "United States", "geoPoint": {"lat": 40.69365, "lon": -89.58899}}, {"facility": "Research Site", "city": "River Forest", "state": "Illinois", "country": "United States", "geoPoint": {"lat": 41.89781, "lon": -87.81395}}, {"facility": "Research Site", "city": "Indianapolis", "state": "Indiana", "country": "United States", "geoPoint": {"lat": 39.76838, "lon": -86.15804}}, {"facility": "Research Site", "city": "Merrillville", "state": "Indiana", "country": "United States", "geoPoint": {"lat": 41.48281, "lon": -87.33281}}, {"facility": "Research Site", "city": "South Bend", "state": "Indiana", "country": "United States", "geoPoint": {"lat": 41.68338, "lon": -86.25001}}, {"facility": "Research Site", "city": "Topeka", "state": "Kansas", "country": "United States", "geoPoint": {"lat": 39.04833, "lon": -95.67804}}, {"facility": "Research Site", "city": "Wichita", "state": "Kansas", "country": "United States", "geoPoint": {"lat": 37.69224, "lon": -97.33754}}, {"facility": "Research Site", "city": "Owensboro", "state": "Kentucky", "country": "United States", "geoPoint": {"lat": 37.77422, "lon": -87.11333}}, {"facility": "Research Site", "city": "Baton Rouge", "state": "Louisiana", "country": "United States", "geoPoint": {"lat": 30.45075, "lon": -91.15455}}, {"facility": "Research Site", "city": "Bogalusa", "state": "Louisiana", "country": "United States", "geoPoint": {"lat": 30.79102, "lon": -89.84869}}, {"facility": "Research Site", "city": "Marrero", "state": "Louisiana", "country": "United States", "geoPoint": {"lat": 29.89937, "lon": -90.10035}}, {"facility": "Research Site", "city": "Metairie", "state": "Louisiana", "country": "United States", "geoPoint": {"lat": 29.98409, "lon": -90.15285}}, {"facility": "Research Site", "city": "Monroe", "state": "Louisiana", "country": "United States", "geoPoint": {"lat": 32.50931, "lon": -92.1193}}, {"facility": "Research Site", "city": "New Orleans", "state": "Louisiana", "country": "United States", "geoPoint": {"lat": 29.95465, "lon": -90.07507}}, {"facility": "Research Site", "city": "Shreveport", "state": "Louisiana", "country": "United States", "geoPoint": {"lat": 32.52515, "lon": -93.75018}}, {"facility": "Research Site", "city": "Sunset", "state": "Louisiana", "country": "United States", "geoPoint": {"lat": 30.41131, "lon": -92.06845}}, {"facility": "Research Site", "city": "Baltimore", "state": "Maryland", "country": "United States", "geoPoint": {"lat": 39.29038, "lon": -76.61219}}, {"facility": "Research Site", "city": "Bethesda", "state": "Maryland", "country": "United States", "geoPoint": {"lat": 38.98067, "lon": -77.10026}}, {"facility": "Research Site", "city": "Mitchellville", "state": "Maryland", "country": "United States", "geoPoint": {"lat": 38.92511, "lon": -76.74275}}, {"facility": "Research Site", "city": "Montgomery Village", "state": "Maryland", "country": "United States", "geoPoint": {"lat": 39.17677, "lon": -77.19526}}, {"facility": "Research Site", "city": "Wheaton", "state": "Maryland", "country": "United States", "geoPoint": {"lat": 39.03983, "lon": -77.05526}}, {"facility": "Research Site", "city": "Dartmouth", "state": "Massachusetts", "country": "United States", "geoPoint": {"lat": 41.59177, "lon": -70.94115}}, {"facility": "Research Site", "city": "Bay City", "state": "Michigan", "country": "United States", "geoPoint": {"lat": 43.59447, "lon": -83.88886}}, {"facility": "Research Site", "city": "Paw Paw", "state": "Michigan", "country": "United States", "geoPoint": {"lat": 42.21782, "lon": -85.89112}}, {"facility": "Research Site", "city": "Saginaw", "state": "Michigan", "country": "United States", "geoPoint": {"lat": 43.41947, "lon": -83.95081}}, {"facility": "Research Site", "city": "Southfield", "state": "Michigan", "country": "United States", "geoPoint": {"lat": 42.47337, "lon": -83.22187}}, {"facility": "Research Site", "city": "Minneapolis", "state": "Minnesota", "country": "United States", "geoPoint": {"lat": 44.97997, "lon": -93.26384}}, {"facility": "Research Site", "city": "Prentiss", "state": "Mississippi", "country": "United States", "geoPoint": {"lat": 31.5985, "lon": -89.86702}}, {"facility": "Research Site", "city": "Vicksburg", "state": "Mississippi", "country": "United States", "geoPoint": {"lat": 32.35265, "lon": -90.87788}}, {"facility": "Research Site", "city": "Omaha", "state": "Nebraska", "country": "United States", "geoPoint": {"lat": 41.25626, "lon": -95.94043}}, {"facility": "Research Site", "city": "Blackwood", "state": "New Jersey", "country": "United States", "geoPoint": {"lat": 39.80234, "lon": -75.06406}}, {"facility": "Research Site", "city": "Cherry Hill", "state": "New Jersey", "country": "United States", "geoPoint": {"lat": 39.93484, "lon": -75.03073}}, {"facility": "Research Site", "city": "Teaneck", "state": "New Jersey", "country": "United States", "geoPoint": {"lat": 40.8976, "lon": -74.01597}}, {"facility": "Research Site", "city": "Verona", "state": "New Jersey", "country": "United States", "geoPoint": {"lat": 40.82982, "lon": -74.24015}}, {"facility": "Research Site", "city": "Bronx", "state": "New York", "country": "United States", "geoPoint": {"lat": 40.84985, "lon": -73.86641}}, {"facility": "Research Site", "city": "Brooklyn", "state": "New York", "country": "United States", "geoPoint": {"lat": 40.6501, "lon": -73.94958}}, {"facility": "Research Site", "city": "New York", "state": "New York", "country": "United States", "geoPoint": {"lat": 40.71427, "lon": -74.00597}}, {"facility": "Research Site", "city": "Newburgh", "state": "New York", "country": "United States", "geoPoint": {"lat": 41.50343, "lon": -74.01042}}, {"facility": "Research Site", "city": "North Syracuse", "state": "New York", "country": "United States", "geoPoint": {"lat": 43.13479, "lon": -76.12992}}, {"facility": "Research Site", "city": "Rochester", "state": "New York", "country": "United States", "geoPoint": {"lat": 43.15478, "lon": -77.61556}}, {"facility": "Research Site", "city": "Tonawanda", "state": "New York", "country": "United States", "geoPoint": {"lat": 43.02033, "lon": -78.88031}}, {"facility": "Research Site", "city": "Asheville", "state": "North Carolina", "country": "United States", "geoPoint": {"lat": 35.60095, "lon": -82.55402}}, {"facility": "Research Site", "city": "Charlotte", "state": "North Carolina", "country": "United States", "geoPoint": {"lat": 35.22709, "lon": -80.84313}}, {"facility": "Research Site", "city": "Greensboro", "state": "North Carolina", "country": "United States", "geoPoint": {"lat": 36.07264, "lon": -79.79198}}, {"facility": "Research Site", "city": "Hickory", "state": "North Carolina", "country": "United States", "geoPoint": {"lat": 35.73319, "lon": -81.3412}}, {"facility": "Research Site", "city": "Highpoint", "state": "North Carolina", "country": "United States", "geoPoint": {"lat": 35.95569, "lon": -80.00532}}, {"facility": "Research Site", "city": "Mooresville", "state": "North Carolina", "country": "United States", "geoPoint": {"lat": 35.58486, "lon": -80.81007}}, {"facility": "Research Site", "city": "Winston-Salem", "state": "North Carolina", "country": "United States", "geoPoint": {"lat": 36.09986, "lon": -80.24422}}, {"facility": "Research Site", "city": "Cincinnati", "state": "Ohio", "country": "United States", "geoPoint": {"lat": 39.12713, "lon": -84.51435}}, {"facility": "Research Site", "city": "Cleveland", "state": "Ohio", "country": "United States", "geoPoint": {"lat": 41.4995, "lon": -81.69541}}, {"facility": "Research Site", "city": "Lyndhurst", "state": "Ohio", "country": "United States", "geoPoint": {"lat": 41.52005, "lon": -81.48873}}, {"facility": "Research Site", "city": "Parma", "state": "Ohio", "country": "United States", "geoPoint": {"lat": 41.40477, "lon": -81.72291}}, {"facility": "Research Site", "city": "Toledo", "state": "Ohio", "country": "United States", "geoPoint": {"lat": 41.66394, "lon": -83.55521}}, {"facility": "Research Site", "city": "Oklahoma City", "state": "Oklahoma", "country": "United States", "geoPoint": {"lat": 35.46756, "lon": -97.51643}}, {"facility": "Research Site", "city": "Beaver", "state": "Pennsylvania", "country": "United States", "geoPoint": {"lat": 40.69534, "lon": -80.30478}}, {"facility": "Research Site", "city": "Collegeville", "state": "Pennsylvania", "country": "United States", "geoPoint": {"lat": 40.18566, "lon": -75.45157}}, {"facility": "Research Site", "city": "Harrisburg", "state": "Pennsylvania", "country": "United States", "geoPoint": {"lat": 40.2737, "lon": -76.88442}}, {"facility": "Research Site", "city": "Havertown", "state": "Pennsylvania", "country": "United States", "geoPoint": {"lat": 39.98095, "lon": -75.30852}}, {"facility": "Research Site", "city": "Philadelphia", "state": "Pennsylvania", "country": "United States", "geoPoint": {"lat": 39.95233, "lon": -75.16379}}, {"facility": "Research Site", "city": "Upland", "state": "Pennsylvania", "country": "United States", "geoPoint": {"lat": 39.85261, "lon": -75.38269}}, {"facility": "Research Site", "city": "Yardley", "state": "Pennsylvania", "country": "United States", "geoPoint": {"lat": 40.24566, "lon": -74.846}}, {"facility": "Research Site", "city": "Charleston", "state": "South Carolina", "country": "United States", "geoPoint": {"lat": 32.77657, "lon": -79.93092}}, {"facility": "Research Site", "city": "Columbia", "state": "South Carolina", "country": "United States", "geoPoint": {"lat": 34.00071, "lon": -81.03481}}, {"facility": "Research Site", "city": "Gaffney", "state": "South Carolina", "country": "United States", "geoPoint": {"lat": 35.07179, "lon": -81.64982}}, {"facility": "Research Site", "city": "Greenville", "state": "South Carolina", "country": "United States", "geoPoint": {"lat": 34.85262, "lon": -82.39401}}, {"facility": "Research Site", "city": "Simpsonville", "state": "South Carolina", "country": "United States", "geoPoint": {"lat": 34.73706, "lon": -82.25428}}, {"facility": "Research Site", "city": "Spartanburg", "state": "South Carolina", "country": "United States", "geoPoint": {"lat": 34.94957, "lon": -81.93205}}, {"facility": "Research Site", "city": "Union", "state": "South Carolina", "country": "United States", "geoPoint": {"lat": 34.71541, "lon": -81.62371}}, {"facility": "Research Site", "city": "Chattanooga", "state": "Tennessee", "country": "United States", "geoPoint": {"lat": 35.04563, "lon": -85.30968}}, {"facility": "Research Site", "city": "Dallas", "state": "Texas", "country": "United States", "geoPoint": {"lat": 32.78306, "lon": -96.80667}}, {"facility": "Research Site", "city": "Houston", "state": "Texas", "country": "United States", "geoPoint": {"lat": 29.76328, "lon": -95.36327}}, {"facility": "Research Site", "city": "Killeen", "state": "Texas", "country": "United States", "geoPoint": {"lat": 31.11712, "lon": -97.7278}}, {"facility": "Research Site", "city": "Missouri City", "state": "Texas", "country": "United States", "geoPoint": {"lat": 29.61857, "lon": -95.53772}}, {"facility": "Research Site", "city": "San Antonio", "state": "Texas", "country": "United States", "geoPoint": {"lat": 29.42412, "lon": -98.49363}}, {"facility": "Research Site", "city": "Sugar Land", "state": "Texas", "country": "United States", "geoPoint": {"lat": 29.61968, "lon": -95.63495}}, {"facility": "Research Site", "city": "Sugarland", "state": "Texas", "country": "United States", "geoPoint": {"lat": 29.61968, "lon": -95.63495}}, {"facility": "Research Site", "city": "Waco", "state": "Texas", "country": "United States", "geoPoint": {"lat": 31.54933, "lon": -97.14667}}, {"facility": "Research Site", "city": "Hampton", "state": "Virginia", "country": "United States", "geoPoint": {"lat": 37.02987, "lon": -76.34522}}, {"facility": "Research Site", "city": "Norfolk", "state": "Virginia", "country": "United States", "geoPoint": {"lat": 36.84681, "lon": -76.28522}}, {"facility": "Research Site", "city": "Richmond", "state": "Virginia", "country": "United States", "geoPoint": {"lat": 37.55376, "lon": -77.46026}}, {"facility": "Research Site", "city": "Springfield", "state": "Virginia", "country": "United States", "geoPoint": {"lat": 38.78928, "lon": -77.1872}}]}, "referencesModule": {"seeAlsoLinks": [{"label": "Related Info", "url": "http://www.asthmaclinicaltrials.com"}]}}, "resultsSection": {"participantFlowModule": {"preAssignmentDetails": "The study included a run-in period of 2 weeks when all patients were prescribed budesonide HFA pMDI 160 \u03bcg times 2 actuations BID at individual daily doses and rescue medication, as needed. To be randomized to treatment the patients needed to show pre-dose FEV1 of \u226550%. One patient in the budesonide group did not receive any dose.", "recruitmentDetails": "First patient enrolled on 8 February 2007, the last patient completed the study on 30 November 2009. The study randomized participants only in the United States.", "groups": [{"id": "FG000", "title": "Symbicort", "description": "Symbicort pMDI 160/4.5 ug x 2 actuations (twice daily) BID"}, {"id": "FG001", "title": "Budesonide", "description": "Budesonide HFA pMDI 160 ug x 2 actuations (twice daily) BID"}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "377"}, {"groupId": "FG001", "numSubjects": "365"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "228"}, {"groupId": "FG001", "numSubjects": "240"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "149"}, {"groupId": "FG001", "numSubjects": "125"}]}], "dropWithdraws": [{"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "8"}, {"groupId": "FG001", "numSubjects": "10"}]}, {"type": "Withdrawal by Subject", "reasons": [{"groupId": "FG000", "numSubjects": "44"}, {"groupId": "FG001", "numSubjects": "43"}]}, {"type": "Lost to Follow-up", "reasons": [{"groupId": "FG000", "numSubjects": "43"}, {"groupId": "FG001", "numSubjects": "34"}]}, {"type": "Protocol Violation", "reasons": [{"groupId": "FG000", "numSubjects": "32"}, {"groupId": "FG001", "numSubjects": "24"}]}, {"type": "Pregnancy", "reasons": [{"groupId": "FG000", "numSubjects": "4"}, {"groupId": "FG001", "numSubjects": "2"}]}, {"type": "Physician Decision", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "3"}]}, {"type": "Incorrectly enrolled", "reasons": [{"groupId": "FG000", "numSubjects": "10"}, {"groupId": "FG001", "numSubjects": "3"}]}, {"type": "Intake of prohibited medication", "reasons": [{"groupId": "FG000", "numSubjects": "2"}, {"groupId": "FG001", "numSubjects": "2"}]}, {"type": "Occurence of 2 or more exacerbations", "reasons": [{"groupId": "FG000", "numSubjects": "2"}, {"groupId": "FG001", "numSubjects": "0"}]}, {"type": "Diary or medication non-compliance", "reasons": [{"groupId": "FG000", "numSubjects": "2"}, {"groupId": "FG001", "numSubjects": "4"}]}, {"type": "Abnormal ECG", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "0"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "Symbicort", "description": "Symbicort pMDI 160/4.5 ug x 2 actuations (twice daily) BID"}, {"id": "BG001", "title": "Budesonide", "description": "Budesonide HFA pMDI 160 ug x 2 actuations (twice daily) BID"}, {"id": "BG002", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "377"}, {"groupId": "BG001", "value": "365"}, {"groupId": "BG002", "value": "742"}]}], "measures": [{"title": "Age Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "Years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "36.19", "spread": "15.67"}, {"groupId": "BG001", "value": "38.35", "spread": "15.22"}, {"groupId": "BG002", "value": "37.27", "spread": "15.48"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "249"}, {"groupId": "BG001", "value": "232"}, {"groupId": "BG002", "value": "481"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "128"}, {"groupId": "BG001", "value": "133"}, {"groupId": "BG002", "value": "261"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Total Number of Asthma Exacerbations", "description": "An exacerbation was defined as symptomatic worsening requiring oral/systemic glucocorticoid therapy and/or emergency room visit and/or urgent care center visit and/or hospitalization.", "populationDescription": "The full analysis set, consisting of all randomized patients who received at least one dose of randomized study medication and for whom data were collected after randomization.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Exacerbations", "timeFrame": "52 Weeks", "groups": [{"id": "OG000", "title": "Symbicort", "description": "Symbicort pMDI 160/4.5 ug x 2 actuations (twice daily) BID"}, {"id": "OG001", "title": "Budesonide", "description": "Budesonide HFA pMDI 160 ug x 2 actuations (twice daily) BID"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "377"}, {"groupId": "OG001", "value": "364"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "36", "spread": "NA"}, {"groupId": "OG001", "value": "61", "spread": "NA"}]}]}]}, {"type": "SECONDARY", "title": "Asthma Exacerbations", "description": "Number of participants with at least 1 exacerbation", "populationDescription": "The full analysis set, consisting of all randomized patients who received at least one dose of randomized study medication and for whom data were collected after randomization.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Participants", "timeFrame": "52 Weeks", "groups": [{"id": "OG000", "title": "Symbicort", "description": "Symbicort pMDI 160/4.5 ug x 2 actuations (twice daily) BID"}, {"id": "OG001", "title": "Budesonide", "description": "Budesonide HFA pMDI 160 ug x 2 actuations (twice daily) BID"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "377"}, {"groupId": "OG001", "value": "364"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "29", "lowerLimit": "-1.01", "upperLimit": "0.79"}, {"groupId": "OG001", "value": "51", "lowerLimit": "-1.23", "upperLimit": "0.61"}]}]}]}, {"type": "SECONDARY", "title": "QT Interval Corrected Using the Fridericia Formula Measured Via Electrocardiogram (ECG)", "description": "QT interval corrected using the Fridericia formula \\[QTc (Frid)\\] - Change from baseline to end of treatment", "populationDescription": "The full analysis set, consisting of all randomized patients who received at least one dose of randomized study medication and for whom data were collected after randomization.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "msec", "timeFrame": "Baseline and 52 weeks", "groups": [{"id": "OG000", "title": "Symbicort", "description": "Symbicort pMDI 160/4.5 ug x 2 actuations (twice daily) BID"}, {"id": "OG001", "title": "Budesonide", "description": "Budesonide HFA pMDI 160 ug x 2 actuations (twice daily) BID"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "377"}, {"groupId": "OG001", "value": "364"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.11", "lowerLimit": "-1.01", "upperLimit": "0.79"}, {"groupId": "OG001", "value": "-0.31", "lowerLimit": "-1.23", "upperLimit": "0.61"}]}]}]}, {"type": "SECONDARY", "title": "Number of Patients With Shift From Normal to High Rate of Total Ectopic Ventricular Beats as Measured by 24-hour Holter Monitor Assessment", "description": "Total ectopic ventricular (VE) beats - number of participants with shift from normal (\\<50) to high (\u226550) from baseline to visit 4.", "populationDescription": "Data were available for a subset of patients.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Participants", "timeFrame": "Baseline and 2 weeks (visit 4)", "groups": [{"id": "OG000", "title": "Symbicort", "description": "Symbicort pMDI 160/4.5 ug x 2 actuations (twice daily) BID"}, {"id": "OG001", "title": "Budesonide", "description": "Budesonide HFA pMDI 160 ug x 2 actuations (twice daily) BID"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "59"}, {"groupId": "OG001", "value": "63"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "4"}, {"groupId": "OG001", "value": "3"}]}]}]}, {"type": "SECONDARY", "title": "Number of Patients With Shift From Normal to High Rate of Total Ectopic Supraventricular Beats as Measured by 24-hour Holter Monitor Assessment", "description": "Total ectopic supraventricular (VE) beats - number of participants with shift normal (\\<50) to high (\u226550) from baseline to visit 4.", "populationDescription": "Data were available for a subset of patients", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Participants", "timeFrame": "Baseline and 2 weeks (visit 4)", "groups": [{"id": "OG000", "title": "Symbicort", "description": "Symbicort pMDI 160/4.5 ug x 2 actuations (twice daily) BID"}, {"id": "OG001", "title": "Budesonide", "description": "Budesonide HFA pMDI 160 ug x 2 actuations (twice daily) BID"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "60"}, {"groupId": "OG001", "value": "67"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "4"}, {"groupId": "OG001", "value": "3"}]}]}]}, {"type": "SECONDARY", "title": "Total Number of Ventricular Runs as Measured by 24-hour Holter Monitor Assessment", "description": "Total ventricular runs - number of participants with shift normal (\\<1) to high (\u22651) from baseline to week 2.", "populationDescription": "Data were available for a subset of patients.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Participants", "timeFrame": "Baseline and 2 weeks (visit 4)", "groups": [{"id": "OG000", "title": "Symbicort", "description": "Symbicort pMDI 160/4.5 ug x 2 actuations (twice daily) BID"}, {"id": "OG001", "title": "Budesonide", "description": "Budesonide HFA pMDI 160 ug x 2 actuations (twice daily) BID"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "63"}, {"groupId": "OG001", "value": "74"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "2", "lowerLimit": "13.43", "upperLimit": "18.34"}, {"groupId": "OG001", "value": "1", "lowerLimit": "8.11", "upperLimit": "13.13"}]}]}]}, {"type": "SECONDARY", "title": "Diary Assessments - Rescue-free Day", "description": "Calculated as the number of rescue-free days divided by the number of non missing days in the baseline period times 100%. The results are expressed as the change in % rescue-free days in the baseline period and the active treatment period. A rescue-free day was one in which the patient answered \"no\" to having used rescue medication that day", "populationDescription": "The full analysis set, consisting of all randomized patients who received at least one dose of randomized study medication and for whom data were collected after randomization.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "Percentage of Rescue Free Day", "timeFrame": "baseline and 52 weeks", "groups": [{"id": "OG000", "title": "Symbicort", "description": "Symbicort pMDI 160/4.5 ug x 2 actuations (twice daily) BID"}, {"id": "OG001", "title": "Budesonide", "description": "Budesonide HFA pMDI 160 ug x 2 actuations (twice daily) BID"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "369"}, {"groupId": "OG001", "value": "353"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "15.88", "lowerLimit": "13.43", "upperLimit": "18.34"}, {"groupId": "OG001", "value": "10.62", "lowerLimit": "8.11", "upperLimit": "13.13"}]}]}]}, {"type": "SECONDARY", "title": "Diary Assessments - Symptom-free Day", "description": "Calculated as the number of symptom-free days divided by the number of non missing days in the baseline period times 100%. The results are expressed as the change in % symptom-free days in the baseline period and the active treatment period. A symptom-free day was one in which the patient answered \"no\" to having symptoms that day", "populationDescription": "The full analysis set, consisting of all randomized patients who received at least one dose of randomized study medication and for whom data were collected after randomization.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "percentage of Symptom-free day", "timeFrame": "baseline and 52 weeks", "groups": [{"id": "OG000", "title": "Symbicort", "description": "Symbicort pMDI 160/4.5 ug x 2 actuations (twice daily) BID"}, {"id": "OG001", "title": "Budesonide", "description": "Budesonide HFA pMDI 160 ug x 2 actuations (twice daily) BID"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "369"}, {"groupId": "OG001", "value": "353"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "9.46", "lowerLimit": "7.55", "upperLimit": "11.37"}, {"groupId": "OG001", "value": "7.58", "lowerLimit": "5.62", "upperLimit": "9.53"}]}]}]}, {"type": "SECONDARY", "title": "Diary Assessments - Asthma-control Day", "description": "Calculated as the number of asthma control days divided by the number of non missing days in the baseline period times 100%. The results are expressed as the change in % asthma control days in the baseline period and the active treatment period. An asthma control day was one in which the patient answered \"no\" to having symptoms and \"0\" to the use of rescue medication that day", "populationDescription": "The full analysis set, consisting of all randomized patients who received at least one dose of randomized study medication and for whom data were collected after randomization.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "percentage of Asthma-control day", "timeFrame": "baseline and 52 weeks", "groups": [{"id": "OG000", "title": "Symbicort", "description": "Symbicort pMDI 160/4.5 ug x 2 actuations (twice daily) BID"}, {"id": "OG001", "title": "Budesonide", "description": "Budesonide HFA pMDI 160 ug x 2 actuations (twice daily) BID"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "369"}, {"groupId": "OG001", "value": "353"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "16.68", "lowerLimit": "14.16", "upperLimit": "19.21"}, {"groupId": "OG001", "value": "11.62", "lowerLimit": "9.04", "upperLimit": "14.20"}]}]}]}, {"type": "SECONDARY", "title": "Onset of Effect Questionnaire (OEQ)", "description": "Number of participants with positive response to Item 2 in questionnaire \"During the past week,you could feel your study medication begin to work right away. A positive response was defined as a response of \"strongly agree\" or \"somewhat agree\"", "populationDescription": "The full analysis set, consisting of all randomized patients who received at least one dose of randomized study medication and for whom data were collected after randomization.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Participants", "timeFrame": "1 week", "groups": [{"id": "OG000", "title": "Symbicort", "description": "Symbicort pMDI 160/4.5 ug x 2 actuations (twice daily) BID"}, {"id": "OG001", "title": "Budesonide", "description": "Budesonide HFA pMDI 160 ug x 2 actuations (twice daily) BID"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "377"}, {"groupId": "OG001", "value": "364"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "172"}, {"groupId": "OG001", "value": "158"}]}]}]}, {"type": "SECONDARY", "title": "Onset of Effect Questionnaire (OEQ)", "description": "Number of participants with positive response to Item 5 in questionnaire \"During the past week, you were satisfied with how quickly you felt your study medication begin to work.\" The scale was scored on a 5-point Likert scale from strongly agree to strongly disagree. A positive response was defined as a response of \"strongly agree\" or \"somewhat agree\"", "populationDescription": "The full analysis set, consisting of all randomized patients who received at least one dose of randomized study medication and for whom data were collected after randomization.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Participants", "timeFrame": "1 week", "groups": [{"id": "OG000", "title": "Symbicort", "description": "Symbicort pMDI 160/4.5 ug x 2 actuations (twice daily) BID"}, {"id": "OG001", "title": "Budesonide", "description": "Budesonide HFA pMDI 160 ug x 2 actuations (twice daily) BID"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "377"}, {"groupId": "OG001", "value": "364"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "165", "lowerLimit": "46.19", "upperLimit": "49.80"}, {"groupId": "OG001", "value": "157", "lowerLimit": "43.95", "upperLimit": "47.33"}]}]}]}, {"type": "SECONDARY", "title": "Peak Expiratory Flow (PEF) in Morning", "description": "Change in AM PEF from baseline (mean over the 2 weeks run-in) to the average of the randomized treatment period.", "populationDescription": "The full analysis set, consisting of all randomized patients who received at least one dose of randomized study medication and for whom data were collected after randomization.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "Liters/minute", "timeFrame": "baseline and 52 weeks", "groups": [{"id": "OG000", "title": "Symbicort", "description": "Symbicort pMDI 160/4.5 ug x 2 actuations (twice daily) BID"}, {"id": "OG001", "title": "Budesonide", "description": "Budesonide HFA pMDI 160 ug x 2 actuations (twice daily) BID"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "364"}, {"groupId": "OG001", "value": "349"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "30.13", "lowerLimit": "24.38", "upperLimit": "35.87"}, {"groupId": "OG001", "value": "19.73", "lowerLimit": "13.86", "upperLimit": "25.59"}]}]}]}, {"type": "SECONDARY", "title": "Forced Expiratory Volume in One Second (FEV1)", "description": "Change in pre-dose FEV1 from baseline (end of run-in, visit 3) to the average of the randomized treatment period", "populationDescription": "The full analysis set, consisting of all randomized patients who received at least one dose of randomized study medication and for whom data were collected after randomization.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "Litres", "timeFrame": "baseline and 52 weeks", "groups": [{"id": "OG000", "title": "Symbicort", "description": "Symbicort pMDI 160/4.5 ug x 2 actuations (twice daily) BID"}, {"id": "OG001", "title": "Budesonide", "description": "Budesonide HFA pMDI 160 ug x 2 actuations (twice daily) BID"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "359"}, {"groupId": "OG001", "value": "354"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.08", "lowerLimit": "0.05", "upperLimit": "0.11"}, {"groupId": "OG001", "value": "-0.01", "lowerLimit": "-0.04", "upperLimit": "0.01"}]}]}]}, {"type": "SECONDARY", "title": "Asthma Treatment Satisfaction Measure (ATSM)", "description": "Overall score - change from baseline to end of treatment. For 11 individual attributes, expectations were subtracted from the outcomes. This difference and the importance rating were combined in a weighted average which was then multiplied by the raw satisfaction measure. The final derived satisfaction measure was transformed to a 0 to 100 scale, with higher scores representing greater satisfaction.", "populationDescription": "The full analysis set, consisting of all randomized patients who received at least one dose of randomized study medication and for whom data were collected after randomization.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "units on a scale", "timeFrame": "Baseline and 52 weeks", "groups": [{"id": "OG000", "title": "Symbicort", "description": "Symbicort pMDI 160/4.5 ug x 2 actuations (twice daily) BID"}, {"id": "OG001", "title": "Budesonide", "description": "Budesonide HFA pMDI 160 ug x 2 actuations (twice daily) BID"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "203"}, {"groupId": "OG001", "value": "232"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "47.99", "lowerLimit": "46.19", "upperLimit": "49.80"}, {"groupId": "OG001", "value": "45.64", "lowerLimit": "43.95", "upperLimit": "47.33"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "5", "eventGroups": [{"id": "EG000", "title": "Symbicort", "description": "Symbicort pMDI 160/4.5 ug x 2 actuations (twice daily) BID", "seriousNumAffected": 12, "seriousNumAtRisk": 377, "otherNumAffected": 98, "otherNumAtRisk": 377}, {"id": "EG001", "title": "Budesonide", "description": "Budesonide HFA pMDI 160 ug x 2 actuations (twice daily) BID", "seriousNumAffected": 15, "seriousNumAtRisk": 365, "otherNumAffected": 84, "otherNumAtRisk": 365}], "seriousEvents": [{"term": "Oesophageal Fistula", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 377}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 365}]}, {"term": "Small Intestinal Obstruction", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 377}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 365}]}, {"term": "Cellulitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 377}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 365}]}, {"term": "Gastroenteritis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 377}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 365}]}, {"term": "Pneumonia", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 377}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 365}]}, {"term": "Pneumonia Bacterial", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 377}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 365}]}, {"term": "Subcutaneous Abscess", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 377}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 365}]}, {"term": "Ankle Fracture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 377}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 365}]}, {"term": "Foreign Body Trauma", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 377}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 365}]}, {"term": "Gun Shot Wound", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 377}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 365}]}, {"term": "Hip Fracture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 377}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 365}]}, {"term": "Osteoarthritis", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 377}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 365}]}, {"term": "Uterine Leiomyoma", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 377}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 365}]}, {"term": "Cerebrovascular Accident", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 377}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 365}]}, {"term": "Headache", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 377}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 365}]}, {"term": "Migraine", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 377}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 365}]}, {"term": "Anxiety", "organSystem": "Psychiatric disorders", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 377}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 365}]}, {"term": "Depression", "organSystem": "Psychiatric disorders", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 377}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 365}]}, {"term": "Schizophrenia", "organSystem": "Psychiatric disorders", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 377}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 365}]}, {"term": "Calculus Urinary", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 377}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 365}]}, {"term": "Haemorrhagic Ovarian Cyst", "organSystem": "Reproductive system and breast disorders", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 377}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 365}]}, {"term": "Ovarian Mass", "organSystem": "Reproductive system and breast disorders", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 377}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 365}]}, {"term": "Asthma", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 377}, {"groupId": "EG001", "numAffected": 4, "numAtRisk": 365}]}, {"term": "Angioedema", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 377}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 365}]}], "otherEvents": [{"term": "Nasopharyngitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 26, "numAtRisk": 377}, {"groupId": "EG001", "numAffected": 29, "numAtRisk": 365}]}, {"term": "Sinusitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 15, "numAtRisk": 377}, {"groupId": "EG001", "numAffected": 23, "numAtRisk": 365}]}, {"term": "Viral Upper Respiratory Tract Infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 22, "numAtRisk": 377}, {"groupId": "EG001", "numAffected": 16, "numAtRisk": 365}]}, {"term": "Headache", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 36, "numAtRisk": 377}, {"groupId": "EG001", "numAffected": 27, "numAtRisk": 365}]}, {"term": "Oropharyngeal Pain", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 19, "numAtRisk": 377}, {"groupId": "EG001", "numAffected": 9, "numAtRisk": 365}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true, "otherDetails": "The PI may use the Multi-Center Study Results and the Site Data for the limited purpose of his or her own research and academic analysis until the earlier of the publication of the first Multi-Center Study at all participating sites"}, "pointOfContact": {"title": "Gerard Lynch", "organization": "AstraZeneca", "email": "aztrial_results_posting@astrazeneca.com"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24"}, "conditionBrowseModule": {"meshes": [{"id": "D000001249", "term": "Asthma"}], "ancestors": [{"id": "D000001982", "term": "Bronchial Diseases"}, {"id": "D000012140", "term": "Respiratory Tract Diseases"}, {"id": "D000008173", "term": "Lung Diseases, Obstructive"}, {"id": "D000008171", "term": "Lung Diseases"}, {"id": "D000012130", "term": "Respiratory Hypersensitivity"}, {"id": "D000006969", "term": "Hypersensitivity, Immediate"}, {"id": "D000006967", "term": "Hypersensitivity"}, {"id": "D000007154", "term": "Immune System Diseases"}], "browseLeaves": [{"id": "M4556", "name": "Asthma", "asFound": "Asthma", "relevance": "HIGH"}, {"id": "M5258", "name": "Bronchial Diseases", "relevance": "LOW"}, {"id": "M14977", "name": "Respiratory Tract Diseases", "relevance": "LOW"}, {"id": "M11168", "name": "Lung Diseases", "relevance": "LOW"}, {"id": "M11170", "name": "Lung Diseases, Obstructive", "relevance": "LOW"}, {"id": "M10018", "name": "Hypersensitivity", "relevance": "LOW"}, {"id": "M14967", "name": "Respiratory Hypersensitivity", "relevance": "LOW"}, {"id": "M10020", "name": "Hypersensitivity, Immediate", "relevance": "LOW"}, {"id": "M10200", "name": "Immune System Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC08", "name": "Respiratory Tract (Lung and Bronchial) Diseases"}, {"abbrev": "BC20", "name": "Immune System Diseases"}, {"abbrev": "All", "name": "All Conditions"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000019819", "term": "Budesonide"}, {"id": "D000068759", "term": "Formoterol Fumarate"}, {"id": "D000069502", "term": "Budesonide, Formoterol Fumarate Drug Combination"}], "ancestors": [{"id": "D000000893", "term": "Anti-Inflammatory Agents"}, {"id": "D000001993", "term": "Bronchodilator Agents"}, {"id": "D000001337", "term": "Autonomic Agents"}, {"id": "D000018373", "term": "Peripheral Nervous System Agents"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}, {"id": "D000018927", "term": "Anti-Asthmatic Agents"}, {"id": "D000019141", "term": "Respiratory System Agents"}, {"id": "D000005938", "term": "Glucocorticoids"}, {"id": "D000006728", "term": "Hormones"}, {"id": "D000006730", "term": "Hormones, Hormone Substitutes, and Hormone Antagonists"}, {"id": "D000058666", "term": "Adrenergic beta-2 Receptor Agonists"}, {"id": "D000000318", "term": "Adrenergic beta-Agonists"}, {"id": "D000000322", "term": "Adrenergic Agonists"}, {"id": "D000018663", "term": "Adrenergic Agents"}, {"id": "D000018377", "term": "Neurotransmitter Agents"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}], "browseLeaves": [{"id": "M21711", "name": "Budesonide", "asFound": "Of 1", "relevance": "HIGH"}, {"id": "M304", "name": "Formoterol Fumarate", "asFound": "Nicotine", "relevance": "HIGH"}, {"id": "M452", "name": "Budesonide, Formoterol Fumarate Drug Combination", "asFound": "Early Stage", "relevance": "HIGH"}, {"id": "M4217", "name": "Anti-Inflammatory Agents", "relevance": "LOW"}, {"id": "M5269", "name": "Bronchodilator Agents", "relevance": "LOW"}, {"id": "M20963", "name": "Anti-Asthmatic Agents", "relevance": "LOW"}, {"id": "M21137", "name": "Respiratory System Agents", "relevance": "LOW"}, {"id": "M9047", "name": "Glucocorticoids", "relevance": "LOW"}, {"id": "M9789", "name": "Hormones", "relevance": "LOW"}, {"id": "M9788", "name": "Hormone Antagonists", "relevance": "LOW"}, {"id": "M20746", "name": "Adrenergic Agents", "relevance": "LOW"}, {"id": "M3670", "name": "Adrenergic beta-Agonists", "relevance": "LOW"}, {"id": "M3673", "name": "Adrenergic Agonists", "relevance": "LOW"}, {"id": "M20504", "name": "Neurotransmitter Agents", "relevance": "LOW"}], "browseBranches": [{"abbrev": "Infl", "name": "Anti-Inflammatory Agents"}, {"abbrev": "Resp", "name": "Respiratory System Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}]}}, "hasResults": true}